Skip to main content
    T

    Thermo Fisher Scientific Inc (TMO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $691.77
    -8.45 (-1.21%)

    Market Cap: $259.44B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Thermo Fisher Scientific Inc (TMO) Financials: Revenue, Profit and Cash Flow

    Updated Oct 21, 2026. Financial statements from company filings, amounts in US dollars.

    Thermo Fisher Scientific reported revenue of $44.56B for the fiscal year ended Dec 31, 2025, up 3.9% from the year before. That year, net income was $6.72B with a net margin of 15.1%, operating cash flow was $7.82B and free cash flow was $6.29B. The quarter ended Sep 30, 2026 had revenue of $12.14B and net income of $1.73B.

    Revenue and Margins

    The operating margin was 17.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $18.27B, a compound annual rate of 10.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$44.56B+3.9%40.9%17.4%15.1%
    Dec 2024$42.88B+0.1%41.3%17.1%14.8%
    Dec 2023$42.86B-4.6%39.9%16.0%13.9%
    Dec 2022$44.91B+14.5%42.2%18.7%15.5%
    Dec 2021$39.21B+21.7%50.1%25.6%19.7%
    Dec 2020$32.22B+26.1%49.7%24.2%19.8%
    Dec 2019$25.54B+4.9%44.4%18.0%14.5%
    Dec 2018$24.36B+16.4%44.6%15.5%12.1%
    Dec 2017$20.92B+14.5%45.2%14.2%10.6%
    Dec 2016$18.27BN/A45.8%13.5%11.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 6.0% from the year before. In the quarter ended Sep 2026, net income rose 6.8% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$44.56B$42.88B$42.86B$44.91B$39.21B$32.22B$25.54B$24.36B$20.92B$18.27B
    Cost of revenue$26.32B$25.18B$25.76B$25.94B$19.57B$16.21B$14.21B$13.50B$11.47B$9.90B
    Gross profit$18.24B$17.70B$17.10B$18.97B$19.64B$16.00B$11.33B$10.86B$9.45B$8.37B
    Research and development$1.40B$1.39B$1.34B$1.47B$1.41B$1.18B$1.00B$967.00M$887.00M$754.00M
    Operating income$7.75B$7.34B$6.86B$8.39B$10.03B$7.79B$4.59B$3.78B$2.96B$2.46B
    Net income$6.72B$6.34B$5.96B$6.96B$7.73B$6.38B$3.70B$2.94B$2.23B$2.02B
    EBITDA$10.51B$10.46B$10.20B$11.67B$11.93B$10.04B$6.80B$6.06B$4.97B$3.78B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$12.14B$11.99B$11.01B$12.21B$11.12B$10.86B$10.36B$11.39B$10.60B$10.54B$10.35B$10.89B
    Gross profit$5.13B$4.88B$4.43B$5.01B$4.58B$4.41B$4.24B$4.82B$4.33B$4.35B$4.21B$4.39B
    Operating income$2.26B$2.09B$1.86B$2.25B$1.94B$1.83B$1.72B$2.02B$1.84B$1.82B$1.66B$1.85B
    Net income$1.73B$1.74B$1.66B$1.97B$1.62B$1.62B$1.51B$1.82B$1.63B$1.55B$1.33B$1.61B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $39.38B exceeded cash and equivalents by $29.53B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$110.34B$97.32B$98.73B$97.15B$95.12B$69.05B$58.38B$56.23B$56.67B$45.91B
    Current assets$28.71B$22.14B$24.59B$25.23B$20.11B$21.96B$11.89B$10.63B$9.42B$7.02B
    Cash and equivalents$9.85B$4.01B$8.08B$8.52B$4.48B$10.32B$2.40B$2.10B$1.33B$786.00M
    Total liabilities$56.81B$47.65B$51.88B$53.01B$54.15B$34.53B$28.71B$28.65B$31.26B$24.37B
    Short-term debt$3.53B$2.21B$3.61B$5.58B$2.54B$2.63B$676.00M$1.27B$2.13B$1.25B
    Long-term debt$35.85B$29.06B$31.31B$28.91B$32.33B$19.11B$17.08B$17.72B$18.87B$15.37B
    Shareholder equity$53.41B$49.58B$46.73B$43.98B$40.79B$34.51B$29.68B$27.59B$25.41B$21.54B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$114.23B$113.17B$113.28B$110.34B$103.02B$101.23B$99.04B$97.32B$100.36B$98.50B$97.09B$98.73B
    Total liabilities$59.34B$60.37B$61.22B$56.81B$51.87B$50.63B$49.56B$47.65B$51.26B$50.96B$51.47B$51.88B
    Cash and equivalents$5.46B$4.06B$3.25B$9.86B$1.98B$4.58B$4.13B$4.02B$4.64B$7.07B$5.50B$8.08B
    Shareholder equity$54.76B$52.68B$51.93B$53.41B$51.02B$50.51B$49.39B$49.58B$48.99B$47.43B$45.52B$46.73B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 80.4% of operating cash flow. Dividends and share repurchases together came to 57.9% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$7.82B$8.67B$8.41B$9.15B$9.31B$8.29B$4.97B$4.54B$4.00B$3.26B
    Capital expenditures$1.52B$1.40B$1.48B$2.24B$2.52B$1.47B$926.00M$758.00M$508.00M$444.00M
    Free cash flow$6.29B$7.27B$6.93B$6.91B$6.79B$6.82B$4.05B$3.79B$3.50B$2.81B
    Dividends paid$636.00M$583.00M$523.00M$455.00M$395.00M$337.00M$297.00M$266.00M$237.00M$238.00M
    Share repurchases$3.00B$4.00B$3.00B$3.00B$2.00B$1.50B$1.50B$500.00M$750.00M$1.25B
    Investing cash flow-$4.05B-$5.84B-$5.14B-$2.16B-$21.93B-$1.51B-$1.49B-$1.25B-$7.73B-$5.52B
    Financing cash flow$1.80B-$6.79B-$3.62B-$2.81B$6.58B$959.00M-$3.12B-$2.24B$3.85B$2.76B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$2.55B$2.13B$1.19B$3.46B$2.24B$1.40B$723.00M$3.29B$2.17B$1.96B$1.25B$3.72B
    Capital expenditures$437.00M$450.00M$376.00M$465.00M$404.00M$294.00M$362.00M$480.00M$272.00M$301.00M$347.00M$405.00M
    Free cash flow$2.11B$1.68B$816.00M$2.99B$1.83B$1.10B$361.00M$2.81B$1.89B$1.66B$904.00M$3.32B
    Last 12 quarters

    Frequently Asked Questions About TMO

    What is Thermo Fisher Scientific's annual revenue?

    Thermo Fisher Scientific reported revenue of $44.56B for the fiscal year ended Dec 31, 2025.

    How fast is Thermo Fisher Scientific's revenue growing?

    Revenue was up 3.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.3%.

    Is Thermo Fisher Scientific profitable?

    Yes. Thermo Fisher Scientific reported net income of $6.72B for the fiscal year ended Dec 31, 2025, with a net margin of 15.1%.

    How much free cash flow does TMO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $7.82B minus capital expenditures of $1.52B produced free cash flow of $6.29B.

    How much debt does Thermo Fisher Scientific have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $35.85B, short-term debt of $3.53B and cash and equivalents of $9.85B.